Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Adult Nasal Type Extranodal NK/T-cell Lymphoma: early-phase trial registry
A small indexed set (14 trials) with no open enrollment listed right now.
Corpus placement: #1,230 of 28,707 conditions by registered trial count.
14 US clinical trials · none currently recruiting · #1,230 of 28,707 conditions by registered trial count
Adult Nasal Type Extranodal NK/T-cell Lymphoma: 14 US clinical trials tracked, none currently recruiting.
Adult Nasal Type Extranodal NK/T-cell Lymphoma is the subject of 14 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 4 of these trials.
Enrollment posture brief
Registry condition adult-nasal-type-extranodal-nkt-cell-lymphoma
OPEN 0 | RECR 0% | LATE 0 | EARLY 14 | RANK #1230 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Adult Nasal Type Extranodal NK/T-cell Lymphoma has no open enrollment in this registry pull (14 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Adult Nasal Type Extranodal NK/T-cell Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Adult Nasal Type Extranodal NK/T-cell Lymphoma is recruiting below its size-band peers.
0 of 14 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Adult Nasal Type Extranodal NK/T-cell Lymphoma research.
National Cancer Institute (NCI) accounts for 4 of 14 trials (28.6%). 9 distinct sponsors appear on at least one study for this condition label.
-
Most Adult Nasal Type Extranodal NK/T-cell Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 30 among the 14 trials that report a genuine target (sentinel values excluded). 13 of those (92.9%) plan for fewer than 100 participants.
-
Adult Nasal Type Extranodal NK/T-cell Lymphoma research is mostly interventional.
14 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
14 total, page 1 of 1
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
Northwestern University
NCT02232516
Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma
National Cancer Institute (NCI)
NCT00336063
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
Mayo Clinic
NCT00918333
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
University of Chicago
NCT01839916
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
National Cancer Institute (NCI)
NCT01258998
Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors
National Cancer Institute (NCI)
NCT01326702
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
Mayo Clinic
NCT01261247
Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant
Case Comprehensive Cancer Center
NCT01959477
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
University of Washington
NCT00601718
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer
Fred Hutchinson Cancer Center
NCT00006251
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies
Case Comprehensive Cancer Center
NCT01658319
Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
University of Nebraska
NCT01336920
FAU in Treating Patients With Advanced Solid Tumors or Lymphoma
National Cancer Institute (NCI)
NCT00769288
Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma
Pierluigi Porcu
NCT01129180
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 10 |
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Adult Nasal Type Extranodal NK/T-cell Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Adult Nasal Type Extranodal NK/T-cell Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Adult Nasal Type Extranodal NK/T-cell Lymphoma page
14 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Adult Nasal Type Extranodal NK/T-cell Lymphoma trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- National Cancer Institute (NCI) sponsors the most Adult Nasal Type Extranodal NK/T-cell Lymphoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Adult Nasal Type Extranodal NK/T-cell Lymphoma condition card totals 14 registered trials; most-linked intervention laboratory biomarker analysis; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.